Slough (UK) – 12 February 2025 – UCB has appointed Dr Stevan Shaw as Head of UK Research. In this role he will lead the research activity delivered from the UK hub in Slough, continuing the pursuit of innovation to deliver medicines for people living with severe diseases.

Steve succeeds former Head of UK Research Dr Alistair Henry who became the company’s Chief Scientific Officer in October 2024.

“I am absolutely delighted to take on this role leading our phenomenal team of scientists at our UK campus,” said Steve. “We have a long history of discovering and developing innovative solutions here – four treatments in our current portfolio started life in Slough – and I am looking forward to continuing to stretch our science for the benefit of patients worldwide.”

Steve joined UCB in 1993 and his career has focused on discovering and developing therapeutics for severe immunological diseases. Most recently Steve led the UK research team in inflammatory dermatology and rheumatology and his leadership in this area has been pivotal in advancing projects from target identification to proof-of-concept clinical studies. His expertise has also shaped global strategies, including educating clinicians and guiding investments in multiple indications.

The UK & Ireland is one of UCB’s three global biopharmaceutical research hubs, employing around 10% of the global workforce in national, regional and global roles. As a leading investor in UK life sciences UCB reinvests around 25% of its global revenue back into biopharmaceutical R&D, primarily in immunology in the UK campus.